<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308115">
  <stage>Registered</stage>
  <submitdate>24/06/2009</submitdate>
  <approvaldate>30/06/2009</approvaldate>
  <actrnumber>ACTRN12609000521224</actrnumber>
  <trial_identification>
    <studytitle>A pilot study to examine the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people</studytitle>
    <scientifictitle>Examining the effectiveness, safety and tolerability of 12 weeks of treatment with low-dose quetiapine (100-400 mg/day) in anorexia nervosa patients aged between 15 and 44 years in improving participants' physical and psychological health status</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Astra Zeneca Protocol ID AU-SEA-0002
TGA CTN number 2003/289</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anorexia Nervosa</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Eating disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>oral low-dose quetiapine therapy
100-400 mg/day for a total of 12 weeks, together with treatment as usual (cognitive behavioural therapy (CBT), individual, family, and supportive psychotherapy) for 12 weeks.</interventions>
    <comparator>treatment as usual only, atypical antipsychotics (including quetiapine) were not permitted</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>participants' physical health status (height, weight, blood pressure, heart rate)</outcome>
      <timepoint>baseline, weekly for the first 12 weeks, then at 26 and 52 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>participants' physical health status (liver, kidney and thyroid function, haematological profile, random blood glucose levels, prolactin levels, acetylated haemoglobin (HbAc1) levels, electrocardiogram (ECG)</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Structured Clinical Interview for the Diagnostic and Statistical Manual of Psychiatric Disorders IV (SCID-IV), used for the diagnosis of psychiatric conditions</outcome>
      <timepoint>Week 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Eating Disorder Examination (EDE)</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Psychological symptoms associated with anorexia nervosa as measured by the Eating Disorder Inventory-2 (EDI-2)</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Centre for Epidemiologic Studies Depression Scale (CES-D)</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maudsely Assessment of Delusions Scale (MADS)</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mood and Anxiety Symptom Questionnaire (MASQ)</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Personal Wellbeing Index</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Side effects profiles as measured by the Udvalg for Kliniske Undersogelser (UKU) Side Effects Ratings Scale</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Medication Adherence Rating Scale</outcome>
      <timepoint>Baseline, weeks 12, 26 and 52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>A Diagnostic and Statistical Manual for Psychiatric Disorders IV (DSM-IV) diagnosis of anorexia nervosa
No history of treatment with an atypical antipsychotic, though treatment for less than 7 days was considered acceptable</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>44</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Treatment with an atypical antipsychotic drug for longer than 7 days, comorbid psychotic illness, history of brain infarction or brain surgery, diabetes, an intelligence quotient (IQ) of less than 70</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation was administered by a Research Fellow at the Orygen Youth Health Research Centre (a separate entity to the Eating Disorders Unit)</concealment>
    <sequence>Participants were recruited from the Orygen Youth Health Eating Disorders Clinic, the Royal Melbourne Hospital Eating Disorders Clinic and the Melbourne Clinic. Those who gave their informed consent were assigned to either the treatment or control groups using a computer generated randomised sequence, separate for the three recruitment sites, that was generated and administered by a Research Fellow.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>open-label flexible dose range</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/03/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astra Zeneca Australia</primarysponsorname>
    <primarysponsoraddress>Medical Division
Astra Zeneca Pty Ltd
Alma Rd, North Ryde
NSW 2113</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Astra Zeneca Australia</fundingname>
      <fundingaddress>Medical Division
Astra Zeneca Pty Ltd
Alma Rd, North Ryde
NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Orygen Youth Health Research Centre</sponsorname>
      <sponsoraddress>Locked Bag 10
Parkville
VIC 3052</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study was to determine whether a new antipsychotic medication, quetiapine (Seroquel) is a safe and effective treatment for young people with anorexia nervosa</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NorthWestern Mental Health Research and Ethics Committee</ethicname>
      <ethicaddress>Royal Melbourne Hospital
Grattan Street
Parkville
VIC 3050</ethicaddress>
      <ethicapprovaldate>1/08/2003</ethicapprovaldate>
      <hrec>E/03/029</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Patrick McGorry</name>
      <address>Orygen Youth Health Research Centre
35 Poplar Road 
Parkville
VIC 3052</address>
      <phone>+61 3 9342 2800</phone>
      <fax />
      <email>pmcgorry@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Patrick McGorry</name>
      <address>Orygen Youth Health Research Centre
35 Poplar Road 
Parkville
VIC 3052</address>
      <phone>+61 3 9342 2800</phone>
      <fax />
      <email>pmcgorry@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sherilyn Goldstone</name>
      <address>Orygen Youth Health Research Centre
35 Poplar Road 
Parkville
VIC 3052</address>
      <phone>+61 3 9342 2800</phone>
      <fax />
      <email>sgol@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>